Proteasome inhibitors recent progress and future directions

Marie Wehenkel; Yik Khuan Ho; Kyung Bo Kim

doi:10.1007/978-0-387-69147-3_7

Proteasome inhibitors recent progress and future directions

Marie Wehenkel, Yik Khuan Ho, Kyung Bo Kim

Pharmaceutical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

3 Scopus citations

Abstract

The proteasome continues to be an attractive target for cancer drug discovery and was validated as such by the successful development of bortezomib. Despite its remarkable efficacy, concerns regarding side effects and drug resistance limit the widespread application of bortezomib. Thus, there has been a heightened interest in the development of a new class of proteasome inhibitors. In this chapter, we discuss recent efforts towards the development of proteasome inhibitors. In addition, we discuss a novel class of compounds targeting an alternative proteasome, the immunoproteasome.

Original language	English
Title of host publication	Modulation of Protein Stability in Cancer Therapy
Pages	99-119
Number of pages	21
DOIs	https://doi.org/10.1007/978-0-387-69147-3_7
State	Published - 2009

Keywords

Catalytic β-subunits
Immunoproteasome-specific inhibitors, Activity-based probes
N-terminal nucleophile protease
Pharmacophores
Proteasome inhibitors
Subunit-specific inhibitors
Ubiquitin-proteasome system

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-0-387-69147-3_7

Cite this

@inbook{11874cedfdee4bc0aa0583ecf90c64e4,

title = "Proteasome inhibitors recent progress and future directions",

abstract = "The proteasome continues to be an attractive target for cancer drug discovery and was validated as such by the successful development of bortezomib. Despite its remarkable efficacy, concerns regarding side effects and drug resistance limit the widespread application of bortezomib. Thus, there has been a heightened interest in the development of a new class of proteasome inhibitors. In this chapter, we discuss recent efforts towards the development of proteasome inhibitors. In addition, we discuss a novel class of compounds targeting an alternative proteasome, the immunoproteasome.",

keywords = "Catalytic β-subunits, Immunoproteasome-specific inhibitors, Activity-based probes, N-terminal nucleophile protease, Pharmacophores, Proteasome inhibitors, Subunit-specific inhibitors, Ubiquitin-proteasome system",

author = "Marie Wehenkel and Ho, {Yik Khuan} and Kim, {Kyung Bo}",

year = "2009",

doi = "10.1007/978-0-387-69147-3_7",

language = "English",

isbn = "9780387691435",

pages = "99--119",

booktitle = "Modulation of Protein Stability in Cancer Therapy",

}

TY - CHAP

T1 - Proteasome inhibitors recent progress and future directions

AU - Wehenkel, Marie

AU - Ho, Yik Khuan

AU - Kim, Kyung Bo

PY - 2009

Y1 - 2009

N2 - The proteasome continues to be an attractive target for cancer drug discovery and was validated as such by the successful development of bortezomib. Despite its remarkable efficacy, concerns regarding side effects and drug resistance limit the widespread application of bortezomib. Thus, there has been a heightened interest in the development of a new class of proteasome inhibitors. In this chapter, we discuss recent efforts towards the development of proteasome inhibitors. In addition, we discuss a novel class of compounds targeting an alternative proteasome, the immunoproteasome.

AB - The proteasome continues to be an attractive target for cancer drug discovery and was validated as such by the successful development of bortezomib. Despite its remarkable efficacy, concerns regarding side effects and drug resistance limit the widespread application of bortezomib. Thus, there has been a heightened interest in the development of a new class of proteasome inhibitors. In this chapter, we discuss recent efforts towards the development of proteasome inhibitors. In addition, we discuss a novel class of compounds targeting an alternative proteasome, the immunoproteasome.

KW - Catalytic β-subunits

KW - Immunoproteasome-specific inhibitors, Activity-based probes

KW - N-terminal nucleophile protease

KW - Pharmacophores

KW - Proteasome inhibitors

KW - Subunit-specific inhibitors

KW - Ubiquitin-proteasome system

UR - http://www.scopus.com/inward/record.url?scp=77957134583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957134583&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-69147-3_7

DO - 10.1007/978-0-387-69147-3_7

M3 - Chapter

AN - SCOPUS:77957134583

SN - 9780387691435

SP - 99

EP - 119

BT - Modulation of Protein Stability in Cancer Therapy

ER -

Proteasome inhibitors recent progress and future directions

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this